Market News AIOpen the app

Spyre Therapeutics shares good news about their drug SPY003 after 12 weeks of testing.

MarketRead the original at sec.gov
Good for SYRE

Spyre reported positive 12-week induction topline data for SPY003, meeting the primary endpoint with strong RHI improvement, clinical remission and endoscopic gains; safety was consistent with its drug class.

SYRE · Spyre Therapeutics, Inc.

AI read · Good for SYRE

The AI's read

Spyre Therapeutics announced positive 12-week induction topline data for SPY003 in Phase 2 SKYLINE Part A. The drug met the trial's primary endpoint with a 10.0-point RHI reduction and showed clinical remission and endoscopic improvement, while safety was reported as consistent with the IL-23 class.

Get alerts for SYRE

Follow Spyre Therapeutics, Inc. (SYRE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SYRE
Free on the App Store and Google Play, or on the web.